Approval · Notice of Compliance 33724 · 2024
SYLVANT: Notice of Compliance 33724
Issued July 30, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33724
- Date
- July 30, 2024
- Company
- Recordati Rare Diseases Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative - Change in Product Ownership
Products in this notice
Medicinal ingredients
- SILTUXIMAB 100 MG per VIAL
- SILTUXIMAB 400 MG per VIAL